Procedures
Follow-up study visits with clinicians occurred at weeks 2, 4, 8, 12, 16, 20, and 24 (with a visit window of ±16 days at each visit except the week 24 visit, which had a window of ±6 weeks). Plasma HIV-1 RNA was measured at baseline and every visit from week 4 onward. If any HIV-1 RNA after week 12 was ≥50 copies/mL, or if there was <1 logCD4We monitored adherence with tenofovir diphosphate (TFV-DP) concentrations at baseline, 12 weeks, and 24 weeks, using stored dried blood spot specimens. An indirect method for the quantification of TFV-DP in 50 mL human dried blood spots was adapted from a previously described method [